Moderna, Inc (NASDAQ:MRNA) was spiking higher on Thursday, holding up better than the general markets, which saw the S&P 500 rally over 1% off the open before giving it all back.
On Thursday, the U.S. Food and Drug Administration's Commissioner Robert Califf said at a U.S. House Agriculture subcommittee meeting the agency plans to work to accept Moderna's application for its COVID-19 vaccine for kids under 5 without delay.
